2015 was a memorable year for biopharma, and not just because of Martin Shkreli.
While the “pharma bro” CEO made worldwide headlines for his December 17 arrest, three months after his now-former company hiked the price of Daraprim more than 5,000%, biopharma also had plenty of other news this past year. Some of them were uplifting stories generated by investors, philanthropists, researchers, and even regulators.
